Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC

Geert A. Simkens; Thijs R. van Oudheusden; Daan Nieboer; Ewout W. Steyerberg; Harm J. Rutten; Misha D. Luyer; Simon W. Nienhuijs; Ignace H. de Hingh

doi:10.1245/s10434-016-5211-6

Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC

Geert A. Simkens, Thijs R. van Oudheusden, Daan Nieboer, Ewout W. Steyerberg, Harm J. Rutten, Misha D. Luyer, Simon W. Nienhuijs, Ignace H. de Hingh^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

With the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), long-term survival can be achieved in selected patients with colorectal peritoneal metastases (PM). Patient selection and outcome may be improved significantly with a tool that adequately predicts survival in these patients. This study was designed to validate the peritoneal surface disease severity score (PSDSS) in patients with colorectal PM treated with CRS?+?HIPEC. If performance of the PSDSS was suboptimal (c?

Original language	English
Pages (from-to)	4214-4221
Journal	Annals of Surgical Oncology
Volume	23
Issue number	13
DOIs	https://doi.org/10.1245/s10434-016-5211-6
Publication status	Published - Dec 2016

Access to Document

10.1245/s10434-016-5211-6

Cite this

Simkens, G. A., van Oudheusden, T. R., Nieboer, D., Steyerberg, E. W., Rutten, H. J., Luyer, M. D., Nienhuijs, S. W., & de Hingh, I. H. (2016). Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC. Annals of Surgical Oncology, 23(13), 4214-4221. https://doi.org/10.1245/s10434-016-5211-6

@article{d0f06f60434d4f25aa7eccdcefae91ea,

title = "Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC",

abstract = "With the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), long-term survival can be achieved in selected patients with colorectal peritoneal metastases (PM). Patient selection and outcome may be improved significantly with a tool that adequately predicts survival in these patients. This study was designed to validate the peritoneal surface disease severity score (PSDSS) in patients with colorectal PM treated with CRS?+?HIPEC. If performance of the PSDSS was suboptimal (c?",

author = "Simkens, {Geert A.} and {van Oudheusden}, {Thijs R.} and Daan Nieboer and Steyerberg, {Ewout W.} and Rutten, {Harm J.} and Luyer, {Misha D.} and Nienhuijs, {Simon W.} and {de Hingh}, {Ignace H.}",

year = "2016",

month = dec,

doi = "10.1245/s10434-016-5211-6",

language = "English",

volume = "23",

pages = "4214--4221",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer, Cham",

number = "13",

}

TY - JOUR

T1 - Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC

AU - Simkens, Geert A.

AU - van Oudheusden, Thijs R.

AU - Nieboer, Daan

AU - Steyerberg, Ewout W.

AU - Rutten, Harm J.

AU - Luyer, Misha D.

AU - Nienhuijs, Simon W.

AU - de Hingh, Ignace H.

PY - 2016/12

Y1 - 2016/12

N2 - With the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), long-term survival can be achieved in selected patients with colorectal peritoneal metastases (PM). Patient selection and outcome may be improved significantly with a tool that adequately predicts survival in these patients. This study was designed to validate the peritoneal surface disease severity score (PSDSS) in patients with colorectal PM treated with CRS?+?HIPEC. If performance of the PSDSS was suboptimal (c?

AB - With the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), long-term survival can be achieved in selected patients with colorectal peritoneal metastases (PM). Patient selection and outcome may be improved significantly with a tool that adequately predicts survival in these patients. This study was designed to validate the peritoneal surface disease severity score (PSDSS) in patients with colorectal PM treated with CRS?+?HIPEC. If performance of the PSDSS was suboptimal (c?

U2 - 10.1245/s10434-016-5211-6

DO - 10.1245/s10434-016-5211-6

M3 - Article

C2 - 27027308

SN - 1068-9265

VL - 23

SP - 4214

EP - 4221

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

IS - 13

ER -